The central role of chemistry in 'quality by design approaches to drug development

Future Medicinal Chemistry

Volumn 4, Issue 14, 2012, Pages 1799-1810

  Grewal, Neha K ^a   Leadbeater, Nicholas E ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALLADIUM;

ANALYTIC METHOD; CATALYSIS; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG PURIFICATION; ENVIRONMENTAL FACTOR; GENOTOXICITY; HYDROGENATION; PRIORITY JOURNAL; QUALITY BY DESIGN; REVIEW; RISK ASSESSMENT;

CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG CONTAMINATION; DRUG DESIGN; GREEN CHEMISTRY TECHNOLOGY; HUMANS; PHARMACEUTICAL PREPARATIONS; QUALITY CONTROL; TECHNOLOGY, PHARMACEUTICAL;

EID: 84867352114     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.117     Document Type: Review

References (57)

1. Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm. Res. 25(4), 781-791 (2008).
2. Juran JM. Juran on Quality by Design. Free Press Publisher, NY, USA (1992).
3. Ishikawa K. What is Total Quality Control? The Japanese Way. Prentice-Hall, Englewood Cliffs, NJ, USA, 63-64 (1985).
4. McDermott R, Mikulak R, Beauregard M. The Basics of FMEA. Productive Press, NY, USA (1996).
5. Press D. Guidelines for Failure Modes and Effects Analysis (FMEA) for Medical Devices. CRC Press, Boca Raton, FL, USA (2003).
6. Anastas P, Warner JC. Green Chemistry: Theory and Practice. Oxford University Press, NY, USA (1998).
7. Anastas P, Eghbali N. Green chemistry: principles and practice. Chem. Soc. Rev. 39, 301-312 (2010).
8. Poliakoff M, Licence P. Green Chemistry. Nature 450, 810-812 (2007).
9. Tang SLY, Smith RL, Poliakoff M. Principles of green chemistry: PRODUCTIVELY. Green Chem. 7, 761-762 (2005). (Pubitemid 41619198)
10. Sheldon RA. The E Factor: fifteen years on. Green Chem. 9, 1273-1283 (2007).
11. Chorkendorff I, Niemantsverdriet JW. Concepts of Modern Catalysis and Kinetics (2nd Edition) Wiley-VCH, Weinheim, Germany (2007).
12. Anastas PT, Bartlett LB, Kirchhoff MM, Williamson TC. The role of catalysis in the design, development, and implementation of green, chemistry. Catal. Today 55, 11-22 (2000).
13. Taber GP, Pfisterer DM, Colberg JC. A new and simplified process for preparing N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene] methanamine and a telescoped process for the synthesis of (1S-cis)-4-(3,4- dichlorophenol)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine mandelate: key intermediates in the synthesis of sertraline hydrochloride. Org. Process Res. Dev. 8(3), 385-388 (2004). (Pubitemid 38829032)
14. Reichardt C, Welton T. Solvents and Solvent Effects in Organic Chemistry. Wiley-VCH, Weinheim, Germany (2010).
15. Gopalan AS, Wai CM, Jacobs HK. Supercritical Carbon Dioxide: Separations and Processes. American Chemical Society, Washington, DC, USA (2011).
16. Freemantle M. An Introduction to Ionic Liquids. RSC Publishing, Cambridge, UK (2009).
17. Lindstrom UM. Organic Reactions in Water: Principles, Strategies and Applications. Wiley-Blackwell, Hoboken, NJ, USA (2007).
18. Leadbeater NE. Fast, easy, clean chemistry by using water as a solvent and microwave heating: the Suzuki coupling as an illustration. Chem. Commun. 2881-2902 (2005). (Pubitemid 40917030)
19. Leadbeater NE, Schmink JR. Microwave Heating as a Tool for Sustainable Chemistry. Leadbeater NE (Ed. ). CRC Press, Boca Raton, FL, USA (2010).
20. Looker AR, Ryan MP, Neubert-Langille BJ, Naji R. Risk Assessment of potentially genotoxic impurities within the framework of quality by design. Org. Process Res. Dev. 14, 1032-1036 (2010).
21. Anderson D, Dobrzyska MM, Basaran N. Effect of various genotoxins and reproductive toxins in human lymphocytes and sperm in the comet assay. Teratog. Carcinog. Mutagen. 17, 29-43 (1997). (Pubitemid 27323185)
22. Ashby J, Tennant RW. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the US NTP. Mutat. Res. 257, 229-306 (1991). (Pubitemid 121007619)
23. Muller L, Mauthe RJ, Riley CM et al. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharmacol. 44, 198-211 (2006).
24. Sobol E, Engel ME, Rubitski E, Ku WW, Aubrecht J, Schiestl RH. Genotoxicity profiles of common alkyl halides and esters with alkylating activity. Mutat. Res. 633(2), 80-94 (2007). (Pubitemid 47239489)
25. Leakakos T, Shank RC. Hydrazine genotoxicity in the neonatal rat. Toxicol. Appl. Pharmacol. 126, 295-300 (1994). (Pubitemid 24203196)
26. Snodin DJ. Genotoxic impurities: from structural alerts to qualification. Org. Process Res. Dev. 14, 960-976 (2010).
27. Cheeseman MA, Machuga, EJ, Bailey AB. A tiered approach to threshold of regulation. Food Chem. Toxicol. 37(4), 387-412 (1999). (Pubitemid 29335764)
28. Jacobsen-Kram D, McGovern T. Toxicological overview of impurities in pharmaceutical products. Adv. Drug Deliv. Rev. 59(1), 38-42 (2007). (Pubitemid 46204934)
29. Kroes R, Renwick AG, Cheeseman M et al. structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem. Toxicol. 42, 65-83 (2004). (Pubitemid 37421327)
30. Augustine RL. Heterogeneous Catalysis for the Synthetic Organic Chemist. Marcel Dekker, NY, USA, 473-510 (1996).
31. Walters W, Patrick G, Jeremy W, Jonathan R, Murcko MA. What do medicinal chemists actually make? A 50-year retrospective. J. Med. Chem. 54(19), 6405-6416 (2011).
32. Jang GR, Harris RZ, Lau DT. Pharmacokinetics and its role in small molecule drug discovery research. Med. Res. Rev. 21, 382-396 (2001). (Pubitemid 32751461)
33. Palmer AM. New horizons in drug metabolism, pharmacokinetics and drug discovery. Drug News Perspect. 16, 57-62 (2003). (Pubitemid 36527833)
34. Lajiness MS, Vieth M, Erickson J. Molecular properties that influence oral drug-like behavior. Curr. Opin. Drug Discov. Dev. 7, 470-477 (2004). (Pubitemid 44383553)
35. Vieth M, Siegel M, Higgs R et al. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47, 224-232 (2004). (Pubitemid 38040506)
36. Leeson P, Davis A. Time-related differences in the physical property profiles of oral drugs. J. Med. Chem. 47, 6338-6348 (2004). (Pubitemid 39587257)
37. Lipinski C, Lombardo F, Dominy B, Feeney P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997). (Pubitemid 27046991)
38. Ajay, Bemis GW, Murcko MA. Designing libraries with CNS activity. J. Med. Chem. 42, 4942-4951 (1999).
39. Egan W, Merz K Jr, Baldwin J. Prediction of drug absorption using multivariate statistics. J. Med. Chem. 43, 3867-3877 (2000).
40. Palm K, Stenberg P, Luthman K, Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14, 568-571 (1997). (Pubitemid 27220272)
41. Veber D, Johnson S, Cheng H, Smith B, Ward K. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615-2623 (2002). (Pubitemid 34595232)
42. Lu JJ, Crimin K, Goodwin JT et al. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J. Med. Chem. 47, 6104-6107 (2004). (Pubitemid 39507351)
43. Hou T, Wang J, Zhang W, Xu X. ADME evaluation in drug discovery. Can oral bioavailability in humans be effectively predicted by simple molecular-property based rules? J. Chem. Inf. Model. 47, 460-463 (2007). (Pubitemid 46615948)
44. Blake JF. Examination of the computed molecular properties of compounds selected for clinical development. BioTechniques (Suppl), 16-20 (2003).
45. Oprea TI. Property distribution of drug-related chemical databases. J. Comput. Aided Mol. Des. 14, 251-264 (2000). (Pubitemid 30175944)
46. Schuffenhauer A, Brown N, Selzer P, Ertl P. Relationships between molecular complexity, biological activity, and structural diversity. J. Chem. Inf. Model. 46, 525-535 (2006).
47. Bemis GW, Murcko MA. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39, 2887-2893 (1996). (Pubitemid 26251026)
48. Bemis GW, Murcko MA. The properties of known drugs. 2. Side chains. J. Med. Chem. 42, 5095-5099 (1999). (Pubitemid 30020260)
49. Yan A, Gasteiger J. Prediction of aqueous solubility of organic compounds by topological descriptors. QSAR Comb. Sci. 22, 821-829 (2003). (Pubitemid 38031196)
50. Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52, 6752-6756 (2009).
51. Ritchie TJ, Macdonald SJF. The impact of aromatic ring count on compound developability: are too many aromatic rings aliability in drug design? Drug Discov. Today 14, 1011-1020 (2009).
52. Nassar A-E F, Kamel AM, Clarimont C. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Discov. Today 9(23), 1020-1028 (2004). (Pubitemid 39574558)
53. Park BK, Kitteringham NR, O'Neill PM. Metabolism of fluorine-containing drugs. Ann. Rev. Pharmacol. Toxicol. 41, 443-470 (2001). (Pubitemid 32385895)
54. Rosenblum SB, Huynh T, Afonso A et al. Discovery of 1-(4-fluorophenyl)- (3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl) -2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem. 41(6), 973-980 (1998).
55. Gouverneur V, Müller K. Fluorine in Pharmaceutical and Medicinal Chemistry. Imperial College Press, London, UK (2012).
56. Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J. Med. Chem. 55(10), 4527-4538 (2012).
57. Trist DG. Scientific process, pharmacology and drug discovery. Curr. Opin. Pharmacol. 11(5), 528-533 (2011).